120 related articles for article (PubMed ID: 36646209)
1. Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC.
Dercle L; Fronheiser M; Rizvi NA; Hellmann MD; Maier S; Hayes W; Yang H; Guo P; Fojo T; Schwartz LH; Zhao B; Leung DK
J Thorac Oncol; 2023 May; 18(5):587-598. PubMed ID: 36646209
[TBL] [Abstract][Full Text] [Related]
2. Nomograms integrating CT radiomic and deep learning signatures to predict overall survival and progression-free survival in NSCLC patients treated with chemotherapy.
Chang R; Qi S; Wu Y; Yue Y; Zhang X; Qian W
Cancer Imaging; 2023 Oct; 23(1):101. PubMed ID: 37867196
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab.
Minemura H; Moriya H; Imai H; Sugiyama T; Yamada Y; Higuchi M; Kaira K; Ozaki Y; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Suzuki H; Minato K; Shibata Y
Thorac Cancer; 2020 Dec; 11(12):3521-3527. PubMed ID: 33044045
[TBL] [Abstract][Full Text] [Related]
4. Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics.
Dercle L; Fronheiser M; Lu L; Du S; Hayes W; Leung DK; Roy A; Wilkerson J; Guo P; Fojo AT; Schwartz LH; Zhao B
Clin Cancer Res; 2020 May; 26(9):2151-2162. PubMed ID: 32198149
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
Vokes EE; Ready N; Felip E; Horn L; Burgio MA; Antonia SJ; Arén Frontera O; Gettinger S; Holgado E; Spigel D; Waterhouse D; Domine M; Garassino M; Chow LQM; Blumenschein G; Barlesi F; Coudert B; Gainor J; Arrieta O; Brahmer J; Butts C; Steins M; Geese WJ; Li A; Healey D; Crinò L
Ann Oncol; 2018 Apr; 29(4):959-965. PubMed ID: 29408986
[TBL] [Abstract][Full Text] [Related]
6. Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer.
de Jong EEC; van Elmpt W; Rizzo S; Colarieti A; Spitaleri G; Leijenaar RTH; Jochems A; Hendriks LEL; Troost EGC; Reymen B; Dingemans AC; Lambin P
Lung Cancer; 2018 Oct; 124():6-11. PubMed ID: 30268481
[TBL] [Abstract][Full Text] [Related]
7. CT-derived radiomic analysis for predicting the survival rate of patients with non-small cell lung cancer receiving radiotherapy.
Zhang N; Zhang X; Li J; Ren J; Li L; Dong W; Liu Y
Phys Med; 2023 Mar; 107():102546. PubMed ID: 36796178
[TBL] [Abstract][Full Text] [Related]
8. Discrimination of mediastinal metastatic lymph nodes in NSCLC based on radiomic features in different phases of CT imaging.
Sha X; Gong G; Qiu Q; Duan J; Li D; Yin Y
BMC Med Imaging; 2020 Feb; 20(1):12. PubMed ID: 32024469
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment
Dissaux G; Visvikis D; Da-Ano R; Pradier O; Chajon E; Barillot I; Duvergé L; Masson I; Abgral R; Santiago Ribeiro MJ; Devillers A; Pallardy A; Fleury V; Mahé MA; De Crevoisier R; Hatt M; Schick U
J Nucl Med; 2020 Jun; 61(6):814-820. PubMed ID: 31732678
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive value of histogram analysis in patients with non-small cell lung cancer refractory to platinum treated by nivolumab: A multicentre retrospective study.
Ravanelli M; Agazzi GM; Milanese G; Roca E; Silva M; Tiseo M; Rondi P; Baggi A; Ganeshan B; Muri M; Panni S; Botti C; Sverzellati N; Maroldi R; Berruti A; Farina D
Eur J Radiol; 2019 Sep; 118():251-256. PubMed ID: 31439251
[TBL] [Abstract][Full Text] [Related]
11. CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction.
Vaidya P; Bera K; Gupta A; Wang X; Corredor G; Fu P; Beig N; Prasanna P; Patil PD; Velu PD; Rajiah P; Gilkeson R; Feldman MD; Choi H; Velcheti V; Madabhushi A
Lancet Digit Health; 2020 Mar; 2(3):e116-e128. PubMed ID: 33334576
[TBL] [Abstract][Full Text] [Related]
12. Radiomic-signature changes after early treatment improve the prediction of progression-free survival in patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.
Hou D; Zheng X; Song W; Liu X; Wang S; Zhou L; Tao X; Lv L; Sun Q; Jin Y; Zhang Z; Ding L; Wu N; Zhao S
Acta Radiol; 2023 Mar; 64(3):1194-1204. PubMed ID: 35971221
[TBL] [Abstract][Full Text] [Related]
13. Radiomic signature as a diagnostic factor for histologic subtype classification of non-small cell lung cancer.
Zhu X; Dong D; Chen Z; Fang M; Zhang L; Song J; Yu D; Zang Y; Liu Z; Shi J; Tian J
Eur Radiol; 2018 Jul; 28(7):2772-2778. PubMed ID: 29450713
[TBL] [Abstract][Full Text] [Related]
14. Associations of Radiomic Data Extracted from Static and Respiratory-Gated CT Scans with Disease Recurrence in Lung Cancer Patients Treated with SBRT.
Huynh E; Coroller TP; Narayan V; Agrawal V; Romano J; Franco I; Parmar C; Hou Y; Mak RH; Aerts HJ
PLoS One; 2017; 12(1):e0169172. PubMed ID: 28046060
[TBL] [Abstract][Full Text] [Related]
15. A Comprehensive Nomogram Combining CT Imaging with Clinical Features for Prediction of Lymph Node Metastasis in Stage I-IIIB Non-small Cell Lung Cancer.
Zheng X; Shao J; Zhou L; Wang L; Ge Y; Wang G; Feng F
Ther Innov Regul Sci; 2022 Jan; 56(1):155-167. PubMed ID: 34699046
[TBL] [Abstract][Full Text] [Related]
16. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Borghaei H; Gettinger S; Vokes EE; Chow LQM; Burgio MA; de Castro Carpeno J; Pluzanski A; Arrieta O; Frontera OA; Chiari R; Butts C; Wójcik-Tomaszewska J; Coudert B; Garassino MC; Ready N; Felip E; García MA; Waterhouse D; Domine M; Barlesi F; Antonia S; Wohlleber M; Gerber DE; Czyzewicz G; Spigel DR; Crino L; Eberhardt WEE; Li A; Marimuthu S; Brahmer J
J Clin Oncol; 2021 Mar; 39(7):723-733. PubMed ID: 33449799
[TBL] [Abstract][Full Text] [Related]
17. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
18. Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery.
Kirienko M; Cozzi L; Antunovic L; Lozza L; Fogliata A; Voulaz E; Rossi A; Chiti A; Sollini M
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):207-217. PubMed ID: 28944403
[TBL] [Abstract][Full Text] [Related]
19. Homology-based radiomic features for prediction of the prognosis of lung cancer based on CT-based radiomics.
Kadoya N; Tanaka S; Kajikawa T; Tanabe S; Abe K; Nakajima Y; Yamamoto T; Takahashi N; Takeda K; Dobashi S; Takeda K; Nakane K; Jingu K
Med Phys; 2020 Jun; 47(5):2197-2205. PubMed ID: 32096876
[TBL] [Abstract][Full Text] [Related]
20. CT-Based Radiomic Signature as a Prognostic Factor in Stage IV
Li H; Zhang R; Wang S; Fang M; Zhu Y; Hu Z; Dong D; Shi J; Tian J
Front Oncol; 2020; 10():57. PubMed ID: 32133282
[No Abstract] [Full Text] [Related]
[Next] [New Search]
